Dilutional Coagulopathy in Patients Undergoing Elective Surgery

Blood Coagulation Disorder Clinical Trial

Official title:

Fibrinogen vs Placebo for Improvement of Clot Strength

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00493272
• Other study ID #: 20070037
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 27, 2007
• Last updated: November 30, 2015
• Start date: June 2007
• Est. completion date: April 2008

Study information

• Verified date: November 2015
• Source: University of Aarhus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: The Regional Committee on Biomedical Research EthicsDenmark: National Board of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of the present study is to perform a comprehensive description of haemostasis parameters before and after haemodilution with Hydroxyethyl starch (HES) following acute bleeding during elective surgery. Moreover the study aims to test the in vivo haemostatic potential of fibrinogen concentrate in dilutional coagulopathy caused by HES in a clinical, prospective, placebo-controlled randomised setup.

We hypothesise; a) A coagulopathy is induced following in vivo haemodilution; b) the coagulopathy is improved or partially improved by fibrinogen.

Description:

Background Hydroxyethyl starch (HES) is a group of artificial colloid solutions widely used for plasma expansion and volume resuscitation. HES consist of branched chains of hydroxylated glucose molecules defined by average molecular weight, degree of hydroxyethylation, and C2/C6 ratio. Several clinical reports and in vitro experiments have documented an impaired coagulation system induced by haemodilution with HES and other colloid plasma expanders. The exact mechanisms responsible for HES induced coagulopahty are not fully understood although reduced levels of von Willebrand factor (vWF), acquired platelet dysfunction, reduced factor VIII levels, and dysfunctional fibrinogen polymerization seems to reflect an important aspect of the pathogenesis.

Experimental laboratory studies performed in our centre and verified by several other research groups have shown successful reversal of the colloid plasma expander induced coagulopathy by fibrinogen concentrate.10-13 So far, the present knowledge are based on laboratory experiments and animal studies. Hence, it appears desirable to perform a comprehensive description of haemostasis parameters following HES induced dilutional coagulopathy in an acute clinical bleeding situation.

Materials and Methods

Study design: Clinical, prospective, double-blind, randomised, place-controlled trial. Blood samples:

Primary end point:

Dynamic whole blood clot formation

Secondary end points:

A) Single coagulation factor activities B) Platelet function C) Whole blood clot stability. D) Thrombin generation

Perspectives:

Serious surgical and traumatic bleedings are common and associated with a high mortality rate. The present study can significantly contribute to our overall understanding of the mechanisms involved in HES induced dilutional coagulopathy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 2008
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• > 18 years

• Indication for performing cystectomia

• Written informed consent

Exclusion Criteria:

• Uses of acetyl-salicylic or non-steroid anti-inflammatory drugs 2 days prior to blood sampling.

• Abnormal preoperative coagulations parameters (Platelets, PP, APTT, D- dimer, Fibrinogen, AT, TT)

• Disseminated cancer and/or bone metastasis

• Medical history of ischemic heart disease, claudicatio, or arteriosclerosis

• Medical history of previous thrombo-embolic event

• Renal failure defined as clinical relevant abnormal levels of creatinine

• Liver failure defined as clinical relevant abnormal levels of ALAT

• Hypersensibility to Voluven, Haemocomplettan or ingredients

• Fertile women not using safe contraception

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Blood Coagulation Disorder
• Blood Coagulation Disorders
• Hemostatic Disorders

Intervention

Drug:
• Fibrinogen
Fibrinogen behandling

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital, Department of Anaesthesiology	DK-8200 Aarhus N

Sponsors (1)

Lead Sponsor	Collaborator
Christian Fenger-Eriksen

Country where clinical trial is conducted

Denmark, 

References & Publications (6)

Baldassarre S, Vincent JL. Coagulopathy induced by hydroxyethyl starch. Anesth Analg. 1997 Feb;84(2):451-3. — View Citation

Damon L, Adams M, Stricker RB, Ries C. Intracranial bleeding during treatment with hydroxyethyl starch. N Engl J Med. 1987 Oct 8;317(15):964-5. — View Citation

de Jonge E, Levi M, Büller HR, Berends F, Kesecioglu J. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med. 2001 Nov;27(11):1825-9. Epub 2001 Sep 26. — View Citation

Fenger-Eriksen C, Anker-Møller E, Heslop J, Ingerslev J, Sørensen B. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth. 2005 Mar;94(3):324-9. Epub 2004 Dec 17. — View Citation

Fenger-Eriksen C, Ingerslev J, Sørensen B. Coagulopathy induced by colloid plasma expanders--search for an efficacious haemostatic intervention. Acta Anaesthesiol Scand. 2006 Aug;50(7):899-900. — View Citation

Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg. 1998 Nov;87(5):989-93. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dynamic whole blood clot formation.		60 minutes	No
Secondary	A) Single coagulation factor activities B) Platelet function C) Whole blood clot stability. D) Thrombin generation.		60 minutes	No